News

Christina Y. Weng, MD, MBA, FASRS, highlights findings showing statin use reduced PVR risk by 25% in a propensity-matched cohort of nearly 10,000 patients.

At Retina Society 2026, Emily Eton, MD, discusses a 10-center study finding similar exudate control in Coats disease and Coats-like disease in inherited retinal diseases, with more injections needed in the IRD group.

Non-invasive electrical stimulation delivered through closed eyelids improved retinal structure and photoreceptor function.

Jesse L. Berry, MD, discusses prospective data on aqueous humor liquid biopsy in retinoblastoma and explains how molecular markers from the aqueous are beginning to guide recurrence risk, treatment intensity, and the workup of otherwise diagnostically inaccessible intraocular lesions.

In the latest episode of The Retina TL;DR with Dr. Weng—part 1 of a special two-part series—host Christina Y. Weng, MD, MBA, FASRS, sits down with two of her former residents, now second-year surgical retina fellows, for candid advice on matching, transitioning, and thriving in fellowship.

At Retina Society 2026, Eileen Hwang, MD, PhD, discusses a meta-analysis finding a 1.78 times higher retinal detachment rate in COL2A1 vs COL11A1 Stickler syndrome and the case for prophylactic laser.

At Retina Society 2026, Nimesh Patel, MD, discusses how stage 2 ROP before 34 weeks raises the treatment rate and why he urges early referral and a risk-tailored approach to care.

Charles Wykoff, MD, PhD, reviews LUGANO safety and treatment burden data, including a 42% injection reduction with vorolanib insert vs aflibercept, despite a missed primary end point.

Three residents were honored for their leadership, education and research, and patient care contributions in ophthalmology, optometry, and retina.

Mark P. Breazzano, MD, FACS, shares findings from a TriNetX real-world database analysis on how HIV co-infection influences RPR titers in patients with ocular syphilis.

Chhablani reports revakinagene taroretcel-lwey slowed cavitation volume growth and preserved photoreceptor structure in MacTel type 2.

Dilsher S. Dhoot, MD, FASRS, breaks down the Phase 3 SOL-1 results on intravitreal axitinib hydrogel (OTX-TKI) and aflibercept on vision maintenance.

Talisa Forest (de Carlo), MD, discusses how dynamic complement biomarkers track with artificial intelligence-measured geographic atrophy progression.

K. Thiran Jayasundera, MD, MS, FACS, on how patient interviews shaped a tool capturing functional and psychological burdens overlooked by visual acuity.

One subretinal injection of medium-dose OCU410 gene therapy reduced geographic atrophy growth by up to 32%.

Christine Kay, MD, discusses 4-year REMAIN data showing durable visual acuity gains with MCO-010, a mutation-agnostic intravitreal optogenetic therapy for advanced retinitis pigmentosa.

Remigromig met its BRUNELLO primary end point in DME, with higher PDR and vitreous hemorrhage rates than ranibizumab.

EURETINA President Nicole Eter, MD, picks the sessions busy clinicians should follow at the 26th EURETINA Congress in Vienna, from durability data to AI. She also explains why early referral is still the most effective retina treatment.

Study found anti-VEGF therapy was linked to kidney function decline in patients with diabetic retinopathy or retinal vein occlusion.

At ESCRS 2026, Jascha Wendelstein, MD, noted standard ETDRS visual acuity testing misses functional differences between multifocal IOLs that reading-speed testing reveals.

Helena Noguera Nuñez, MD, discusses a prospective study of the TECNIS Odyssey IOL from ESCRS 2026.

Samantha Harding, MD, discusses how ultra-widefield imaging reduces dilation needs and improves diagnosis in paediatric eye care.

At WSPOS Subspecialty Day during the 44th Congress of the ESCRS in London, Mark Bullimore, PhD, MCOptom, shared early trial data suggesting the Stellest 2.0 lens may slow myopic progression twice as fast as the original.

Hove stresses surgeons who prescribe premium lenses or laser surgery to patients should be willing to have those same treatments themselves when needed.

Emami-Naeini previews Retina Society 2026's shift toward AI-derived, quantitative biomarkers in imaging and therapeutics.

Ana Miguel, MD, PhD, explains how artificial intelligence already outperforms experts in glaucoma screening, expands telemedicine access, and reshapes patient conversations.

Learn who benefits most from Encelto for MacTel type 2, its long-lasting CNTF implant results, and key safety counseling points.

Giuseppe Giannaccare, MD, PhD, FEBOphth, discusses new data on perioperative low-level light therapy for post-cataract dry eye at ESCRS 2026.